Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis | BMJ Neurology Open

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Topic collection

Archive

For authors

About
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

This article has a correction. Please see:

Correction: Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis - July 01, 2021

XML

Short report

Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Karunaratne K, Ahrabian D, Monaghan B, et al

Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis

BMJ Neurology Open 2021;3:e000096. doi: 10.1136/bmjno-2020-000096